Distribution and predictors of haemophilia-related costs in the United Kingdom: analysis of the CHESS I and CHESS II burden of illness studies
UK direct medical and societal costs of haemophilia are substantial. Non-drug DMC were particularly associated with ABR and number of PJs. These findings may be useful for real-world evaluations of the economic burden of haemophilia in the UK.
Authors
- Amit Chhabra (ORCID: https://orcid.org/0000-0002-6115-8253)
- Ione Woollacott
- Enrico Ferri Grazzi (ORCID: https://orcid.org/0000-0002-0567-0260)
- Michael Laffan (ORCID: https://orcid.org/0000-0002-8268-3268)
- Jamie O’Hara (ORCID: https://orcid.org/0000-0001-8262-034X)
- Tom Burke (ORCID: https://orcid.org/0000-0001-6768-1670)
- Jack Brownrigg
- J. Godfrey (ORCID: https://orcid.org/0009-0007-9155-4795)
- Lucy Richardson
Institutions
- University of Chester (GB)
- Pfizer (United Kingdom) (GB)
- Brooke (GB)
- Imperial College London (GB)
- Health and Safety Executive (GB)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1186/s12913-024-11850-y
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- Pfizer
- Sanofi